Glioblastoma multiforme is the most malignant tumor of the glial series. The average survival of patients with this tumor ranges from 6 to 12 months. The case of a patient who survived for more than 11 years after diagnosis of a temporal-occipital glioblastoma which was treated with surgery, radiotherapy and chemotherapy is described. The authors deduce that among patients with glioblastoma multiforme (GM), those with a long disease-free interval after initial diagnosis who undergo multimodal therapy, including aggressive tumor removal, are the most likely long-term survivors (LS). Other factors which appeared to be related to longer survival were younger age and high Karnofsky scores.
AkslenL.A., AndersenK.J., BjerkvigR.: Characteristics of human and rat glioma cells grown in a defined medium.Anticancer Res.,8: 797–804, 1988.
2.
BeckerD.R., BenyoR., RoessmannU.: Glial origin of mon-strocellular tumor. Case report and prolonged survival.J. Neurosurg.,26: 72–77, 1967.
3.
BurgerP.C., GreenS.B.: Patient age, histological features, and length of survival in patients with glioblastoma multiforme.Cancer,59: 1617–1625, 1987.
4.
ChamberlainH.C., SilverP., LevinV.A.: Poorly differentiated glioblastomas of the cerebellum. A study of 18 patients.Cancer,65: 337–340, 1940.
5.
ChandlerK.L., PradosM., MalecM., WilsonC.: Long-term survival in patients with glioblastoma multiforme.Neurosurgery,32: 716–720, 1993.
6.
De TriboletN., DeruazJ.P., ZanderE.: Familial gliomas.Neurochirurgia (Stuttg.),22: 225–228, 1979.
7.
DorwardN.L., HawkinsR.A., WhittleI.R.: Epidermal growth factor receptor activity and clinical outcome in glioblastoma and meningioma.Br. J. Neurosurg.,7: 197–199, 1993.
8.
ElvidgeA.R., BaroneB.M.: Long-term postoperative survival in two cases of glioblastoma multiforme.J. Neurosurg.,22: 382–386, 1965.
9.
GutinP.H., LeibelS.A., WaraW.M., ChoucairA., LevinV.A., PhillipsT.L., SilverP., Da SilvaV., EdwardsM.S.B., DavisR.L., WeaverK.S., LambS.: Recurrent malignant gliomas: Survival following interstitial brachytherapy with high-activity iodine-125 sources.J. Neurosurg.,67: 864–873, 1987.
10.
HatanakaH., SanoK., KitamuraK., FukuiM., MogamiH., UshioY., KuwabaraT., KyumaY., InabaY., HiratsukaH., SuzukyJ., KatakuraR., TakakuraK., HandaH., YamashitaJ.: CT findings in patients with gliomas, surviving more than 10 years.Neurochirurgia (Stuttg.),27: 106–110, 1984.
11.
HelsetA., MorkS.J.: Neoplasms of the central nervous system in Norway. III, Epidemiological characteristics of intracranial gliomas according to histology.APMIS,97: 547–555, 1989.
12.
HiesigerE.M., HayesR.L., PierzD.M., BudzilovichG.N.: Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs).J. Neuro-Oncol.,16: 93–104, 1993.
13.
HollsteinM., SidranskyD., VogelsteinB., HarrisC.C.: p53 mutations in human cancers.Science,253: 49–53, 1991.
14.
HoshinoT., PradosM., WilsonC.B., ChoK.G., LeeK.S., DavisR.L.: Prognostic implications of the bromodeoxyuri-dine labeling index of human gliomas.J. Neurosurg.,71: 335–341, 1989.
15.
HurttM.R., MoossyJ., Donovan-PelusoM., LockerJ.: Amplification of epidermal growth factor receptor gene in gliomas: histopathology and prognosis.J. Neuropathol. Exp. Neurol.,51: 84–90, 1992.
16.
ImperatoJ.P., PaleologosN.A., VickN.A.: Effects of treatment on long-term survivors with malignant astrocytomas.Ann. Neurol.,28: 818–822, 1990.
17.
JarosE., PerryR., AdamL., KellyP.J., CrawfordP.J., KalbagR.M., MendelowA.D., SenguptaR.P., PearsonA.D.J.: Prognostic implications of p53 protein, epidermal growth factor receptor, and Ki-67 labelling in brain tumors.Br. J. Cancer,66: 373–385, 1992.
18.
JelsmaR., BucyP.C.: The treatment of glioblastoma multiforme of the brain.J. Neurosurg.,27: 388–400, 1967.
19.
KepesJ.J.: Pleomorphic xanthoastrocytoma: the birth of a diagnosis and a concept.Brain Pathol.,3: 269–274, 1993.
20.
KleihuesP., BurgerP.C., ScheithauerB.W.: Histological typing of tumors of the central nervous system, 2nd ed., p. 112, Springer Verlag, Berlin, 1993.
21.
KristiansenK., HagenS., KollevoldT., TorvikA., HolmeI., NesbakkenR., HatlevollR., LindgrenM., BrunA., LindgrenS., NotterG., AndersenA.P., ElgenK.: Combined modality therapy of operated astrocytomas grade III and IV. Confirmation of the value of postoperative irradiations and lack of potentiation of bleomycin on survival time: A prospective multicenter trial of the Scandinavian glioblastoma study group.Cancer,47: 649–652, 1981.
22.
LouisD.N.: The p53 gene and protein in human brain tumors.J. Neuropathol. Exp. Neurol.,53: 11–21, 1994.
23.
MargettsJ.C., Kalyan-RamanU.P.: Giant-celled glioblastoma of brain. A clinicopathological and radiological study of ten cases (including immunohistochemistry and ultrastructure).Cancer,63: 524–31, 1989.
24.
MbiddeE.K., SelbyP.J., PerrenT.J., DearnaleyD.P., WhittonA., AshleyS., WorkmanP., BloomH.J., Mc ElwainT.J.: High dose BCNU chemotherapy with autologous bone marrow transplantation and full dose radiotherapy for grade IV astrocytoma.Br. J. Cancer,58: 779–782, 1988.
25.
MoritaM., RosenblumM.K., BilskyM.H., FraserR.A.R., RosenfeldM.R.: Long-term survivors of glioblastoma multiforme: clinical and molecular characteristics.J. Neuro-Oncol.,27: 259–266, 1996.
26.
MurovicJ., TurowskyK., WilsonC.B., HoshinoT., LevinV.: Computerized tomography in the prognosis of malignant gliomas.J. Neurosurg.,65: 799–806, 1986.
27.
NetskyM.G., AugustB., FowlerW.: Longevity of patients with glioblastoma multiforme.J. Neurosurg.,7: 261–268, 1950.
28.
PardoF.S., HsuD.W., Hedley-WhyteE.T., EfirdJ., SchmidtE.V.: High p53 expression is prognostic of overall survival in adult supratentorial astrocytoma patients.J. Neuro-Oncol.,15(suppl.): S19, 1993.
29.
PigottT.J., RobsonD.K., PalmerJ., WardL.M.: Expression of epidermal growth factor receptor in human glioblastoma multiforme.Br. J. Neurosurg.,7: 261–265, 1993.
30.
RoosenN., KiwitJ.C.V., LinsE., SchirmerM., BockW.J.: Adjuvant intraarterial chemotherapy with nimustine in the management of World Health Organization grade IV gliomas of the brain. Experience at the Department of Neurosurgery of Düsseldorf University.Cancer,64: 1984–1994, 1989.
31.
RothJ.G., ElvidgeA.R.: Glioblastoma multiforme: A clinical survey.J. Neurosurg.,17: 736–750, 1960.
32.
RutzH.P., de TriboletN., CalmesJ.M., ChapuisG.: Longtime survival of a patient with glioblastoma and Turcot's syndrome.Case report. J. Neurosurg.,74: 813–815, 1991.
33.
SalcmanM.: Comments (on: Chandler K.L., Prados M.D., Malel M., Wilson C.B.: Long term survival in patients with glioblastoma multiforme).Neurosurgery,5: 716–720, 1993.
34.
SalfordL., BrunA., NirfalkS.: Ten year survival among patients with supratentorial astrocytomas grade III and IV.J. Neurosurg.,68: 506–509, 1988.
35.
TakeuchiK., HoshinoK.: Statistical analysis of factors affecting survival after glioblastoma multiforme. Acta Neu-rochir.(Wien),37: 57–73, 1977.
36.
UllenH., MattsonB., CollinsV.: Long-term survival after malignant glioma. A clinical and histopatological study on the accuracy of the diagnosis in a population-based cancer register.Acta Oncol.,29: 875–878, 1990.
37.
WalkerM.D., AlexanderE.Jr., HuntW.E., MacCarthyC.S., MahaleyM.S., MealeyJ.Jr., NorrelH.A., OwensG., Ran-sonhoffJ., WilsonC.B., GehanE.A., StrikeT.A.: Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial.J. Neurosurg.,49: 333–343, 1978.
38.
WesterK., BjerkvigR., CresseyL., EngerbraatenO., MorkS.: Organ culture of a glioblastoma from a patient with unusually long survival.Neurosurgery3: 428–433, 1994.
39.
WingerM.J., MacDonaldD.R., CairncrossJ.G.: Supratentorial anaplastic gliomas in adults. The prognostic importance of extent of resection and prior low-grade glioma.J. Neurosurg.,71: 487–493, 1989.
